AVEO Pharmaceuticals Inc. pushed its way out the initial public offering window Thursday night, raising $81 million through the sale of 9 million shares for $9 apiece. (BioWorld Today)
Three months after Biogen Idec Inc. failed to acquire Facet Biotech Corp. for $17.50 per share, Abbott is getting the job done with a $27-per-share offer. (BioWorld Today)
Four months after GTx Inc. suffered a devastating FDA setback with lead program toremifene, the biotech's second program - Phase II muscle loss drug Ostarine/MK-2866 - has been discontinued by partner Merck and Co. Inc. (BioWorld Today)
